DIVI'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,016 INR | +4.49% |
|
+9.39% | +2.88% |
| 04-26 | Weak March Quarter Earnings Weigh Down Indian Equities on Friday | MT |
| 04-25 | Divi's Laboratories Plans Up To INR7 Billion Investment to Boost Capacity | MT |
| Sales 2024 * | 76.79B 921M 1.26B | Sales 2025 * | 88.63B 1.06B 1.45B | Capitalization | 1,066B 12.79B 17.48B |
|---|---|---|---|---|---|
| Net income 2024 * | 15.38B 184M 252M | Net income 2025 * | 20.38B 244M 334M | EV / Sales 2024 * | 13.3 x |
| Net cash position 2024 * | 46.03B 552M 755M | Net cash position 2025 * | 48.33B 580M 792M | EV / Sales 2025 * | 11.5 x |
| P/E ratio 2024 * |
69
x | P/E ratio 2025 * |
52.2
x | Employees | 8,433 |
| Yield 2024 * |
0.64% | Yield 2025 * |
0.71% | Free-Float | 47.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on Divi's Laboratories Limited
More recommendations
More press releases
| 1 day | +4.49% | ||
| 1 week | +9.39% | ||
| Current month | +16.57% | ||
| 1 month | +19.26% | ||
| 3 months | +12.22% | ||
| 6 months | +17.71% | ||
| Current year | +2.88% |
1 week
3 675.00
4 039.00
1 month
3 450.004 039.00
Current year
3 350.004 074.40
1 year
3 051.004 074.40
3 years
2 730.005 425.10
5 years
1 466.005 425.10
10 years
532.655 425.10
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 01-08-09 | |
| Founder | 73 | 90-10-11 | |
| Director of Finance/CFO | 74 | 94-11-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 73 | 90-10-11 | |
| Chief Executive Officer | 46 | 01-08-09 | |
| Director/Board Member | - | 14-06-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.68% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4,016 | +4.49% | 1,155,173 |
| 24-04-25 | 3,844 | +0.79% | 835,354 |
| 24-04-24 | 3,814 | +1.20% | 473,558 |
| 24-04-23 | 3,769 | +0.83% | 307,637 |
| 24-04-22 | 3,738 | +1.79% | 439,590 |
Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am
More quotes
Divi's Laboratories Limited is specialized in the development and manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%).
At the end of March 2020, the group has 2 production sites located in India.
Sector
Pharmaceuticals
Calendar
2024-05-26
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
4,016
INR
Average target price
3,442
INR
Spread / Average Target
-14.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.88% | 12.78B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- DIVISLAB Stock
